{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:12:41Z","timestamp":1778274761982,"version":"3.51.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002345","name":"University of T\u00fcbingen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016888","name":"Bayer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009397","name":"Medizinischen Fakult\u00e4t, Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","award":["3007-0-0"],"award-info":[{"award-number":["3007-0-0"]}],"id":[{"id":"10.13039\/501100009397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omton.2026.201140","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:47:17Z","timestamp":1770137237000},"page":"201140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The oncolytic vesicular stomatitis virus VSV-GP shows profound oncolytic activity in NUT-carcinoma cell lines"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4357-7923","authenticated-orcid":false,"given":"Rieka C.","family":"Buchenau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Beil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Berchtold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Smirnow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Fehrenbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneli","family":"Vollert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Schoeps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Kleemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich M.","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6709-9135","authenticated-orcid":false,"given":"Linus D.","family":"Kloker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201140_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/pin.12727","article-title":"NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment","volume":"68","author":"French","year":"2018","journal-title":"Pathol. Int."},{"key":"10.1016\/j.omton.2026.201140_bib2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/JTO.0000000000000545","article-title":"Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations","volume":"10","author":"Sholl","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.omton.2026.201140_bib3","first-page":"3327","article-title":"Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma","volume":"51","author":"Kubonishi","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201140_bib4","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/cncr.30242","article-title":"Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck","volume":"122","author":"Chau","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201140_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12105-010-0174-6","article-title":"NUT gene rearrangement in a poorly-differentiated carcinoma of the submandibular gland","volume":"4","author":"Ziai","year":"2010","journal-title":"Head Neck Pathol."},{"key":"10.1016\/j.omton.2026.201140_bib6","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/PAS.0b013e3181abe120","article-title":"NUT midline carcinoma of the parotid gland with mesenchymal differentiation","volume":"33","author":"den Bakker","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.omton.2026.201140_bib7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-pathol-011811-132438","article-title":"Pathogenesis of NUT midline carcinoma","volume":"7","author":"French","year":"2012","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.omton.2026.201140_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz094","article-title":"An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients","volume":"4","author":"Chau","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.omton.2026.201140_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107496","article-title":"Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients","volume":"189","author":"Kloker","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.omton.2026.201140_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2217\/fvl-2016-0129","article-title":"Designing and building oncolytic viruses","volume":"12","author":"Maroun","year":"2017","journal-title":"Future Virol."},{"key":"10.1016\/j.omton.2026.201140_bib11","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1128\/JVI.77.8.4827-4835.2003","article-title":"Complexes of Poliovirus Serotypes with Their Common Cellular Receptor, CD155","volume":"77","author":"He","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201140_bib12","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-04-0884","article-title":"High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus","volume":"64","author":"Anderson","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201140_bib13","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1553561","article-title":"Identification of the Integrin VLA-2 as a Receptor for Echovirus 1","volume":"255","author":"Bergelson","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201140_bib14","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201140_bib15","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.3390\/cancers13215452","article-title":"Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201140_bib16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/cancers13030544","article-title":"Measles Virus as an Oncolytic Immunotherapy","volume":"13","author":"Engeland","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201140_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201140_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112761","article-title":"Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma","volume":"14","author":"Ohnesorge","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201140_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.995744","article-title":"Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma","volume":"12","author":"Kloker","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201140_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/v16050775","article-title":"Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors","volume":"16","author":"Sotiriadis","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2026.201140_bib21","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/0008-5472.CAN-13-3306","article-title":"Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency","volume":"74","author":"Muik","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201140_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.21","article-title":"Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy","volume":"3","author":"Dold","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201140_bib23","article-title":"Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201140_bib24","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1038\/sj.onc.1209042","article-title":"VSV-tumor selective replication and protein translation","volume":"24","author":"Barber","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2026.201140_bib25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/382726a0","article-title":"Specific cytotoxic T cells eliminate B cells producing virus-neutralizing antibodies [corrected]","volume":"382","author":"Planz","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201140_bib26","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4049\/jimmunol.118.1.348","article-title":"Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement","volume":"118","author":"Welsh","year":"1977","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201140_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3892\/ijo.2013.1914","article-title":"Primary resistance phenomena to oncolytic measles vaccine viruses","volume":"43","author":"Noll","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omton.2026.201140_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21207618","article-title":"Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines","volume":"21","author":"Berchtold","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201140_bib29","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1128\/JVI.77.9.5524-5528.2003","article-title":"The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death","volume":"77","author":"Kopecky","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201140_bib30","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/ijc.31556","article-title":"Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer","volume":"143","author":"Urbiola","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omton.2026.201140_bib31","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1128\/JVI.05640-11","article-title":"Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma","volume":"86","author":"Murphy","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201140_bib32","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1128\/JVI.02305-12","article-title":"Induction of stress granule-like structures in vesicular stomatitis virus-infected cells","volume":"87","author":"Dinh","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201140_bib33","doi-asserted-by":"crossref","first-page":"13512","DOI":"10.1074\/jbc.M501156200","article-title":"Inhibition of host and viral translation during vesicular stomatitis virus infection. eIF2 is responsible for the inhibition of viral but not host translation","volume":"280","author":"Connor","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201140_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1877-1173(09)90004-7","article-title":"Regulation of translation by stress granules and processing bodies","volume":"90","author":"Kedersha","year":"2009","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.omton.2026.201140_bib35","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.molcel.2009.11.020","article-title":"Eukaryotic stress granules: the ins and outs of translation","volume":"36","author":"Buchan","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2026.201140_bib36","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030718","article-title":"TIA-1 Is a Functional Prion-Like Protein","volume":"9","author":"Rayman","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.omton.2026.201140_bib37","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.4161\/cc.6323","article-title":"The eIF2\u03b1 kinases inhibit vesicular stomatitis virus replication independently of eIF2 phosphorylation","volume":"7","author":"Krishnamoorthy","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.omton.2026.201140_bib38","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41467-019-10167-3","article-title":"The structural basis of translational control by eIF2 phosphorylation","volume":"10","author":"Adomavicius","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201140_bib39","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1074\/jbc.274.9.5953","article-title":"Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR","volume":"274","author":"Abraham","year":"1999","journal-title":"J Biol Chem."},{"key":"10.1016\/j.omton.2026.201140_bib40","doi-asserted-by":"crossref","first-page":"38364","DOI":"10.1074\/jbc.M203564200","article-title":"Functional characterization of pkr gene products expressed in cells from mice with a targeted deletion of the N terminus or C terminus domain of PKR","volume":"277","author":"Baltzis","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201140_bib41","doi-asserted-by":"crossref","first-page":"12747","DOI":"10.1128\/JVI.78.23.12747-12761.2004","article-title":"Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR","volume":"78","author":"Baltzis","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201140_bib42","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/sj.emboj.7601073","article-title":"Antiviral effect of the mammalian translation initiation factor 2alpha kinase GCN2 against RNA viruses","volume":"25","author":"Berlanga","year":"2006","journal-title":"Embo j."},{"key":"10.1016\/j.omton.2026.201140_bib43","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1128\/JVI.77.8.4646-4657.2003","article-title":"Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis","volume":"77","author":"Ahmed","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201140_bib44","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1128\/MMBR.64.4.709-724.2000","article-title":"Cytopathogenesis and inhibition of host gene expression by RNA viruses","volume":"64","author":"Lyles","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.omton.2026.201140_bib45","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/embor.2009.179","article-title":"Vesicular stomatitis virus inhibits mitotic progression and triggers cell death","volume":"10","author":"Chakraborty","year":"2009","journal-title":"EMBO Rep."},{"key":"10.1016\/j.omton.2026.201140_bib46","first-page":"304","article-title":"BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201140_bib47","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/onc.2012.487","article-title":"Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma","volume":"32","author":"Thompson-Wicking","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2026.201140_bib48","first-page":"E5352","article-title":"Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma","volume":"114","author":"Wang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201140_bib49","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1073\/pnas.0401449101","article-title":"Two RNA polymerase complexes from vesicular stomatitis virus-infected cells that carry out transcription and replication of genome RNA","volume":"101","author":"Qanungo","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201140_bib50","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1128\/jvi.15.6.1348-1356.1975","article-title":"Both NS and L proteins are required for in vitro RNA synthesis by vesicular stomatitis virus","volume":"15","author":"Emerson","year":"1975","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201140_bib51","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.36922\/td.4904","article-title":"Expert consensus and current landscape of NUT carcinoma: A comprehensive strategy from diagnosis to treatment","volume":"3","author":"Ye","year":"2024","journal-title":"Tumor Discovery"},{"key":"10.1016\/j.omton.2026.201140_bib52","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/annonc\/mdw686","article-title":"Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omton.2026.201140_bib53","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1128\/JVI.02511-10","article-title":"Pseudotyping Vesicular Stomatitis Virus with Lymphocytic Choriomeningitis Virus Glycoproteins Enhances Infectivity for Glioma Cells and Minimizes Neurotropism","volume":"85","author":"Muik","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201140_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009996","article-title":"Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants","volume":"17","author":"Volland","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omton.2026.201140_bib55","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0042-6822(82)90530-X","article-title":"Interferon induction by viruses. VIII. Vesicular stomatitis virus: [+\/-]DI-011 particles induce interferon in the absence of standard virions","volume":"117","author":"Sekellick","year":"1982","journal-title":"Virology"},{"key":"10.1016\/j.omton.2026.201140_bib56","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1074\/jbc.RA118.005868","article-title":"The stress granule protein G3BP1 binds viral dsRNA and RIG-I to enhance interferon-\u03b2 response","volume":"294","author":"Kim","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201140_bib57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tcb.2022.06.010","article-title":"Targeting STING to promote antitumor immunity","volume":"33","author":"Chin","year":"2023","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.omton.2026.201140_bib58","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201140_bib59","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202402602","article-title":"Brd4::Nutm1 fusion gene initiates NUT carcinoma in vivo","volume":"7","author":"Zheng","year":"2024","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.omton.2026.201140_bib60","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1158\/0008-5472.CAN-23-2545","article-title":"The BRD4\u2013NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma","volume":"83","author":"Durall","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201140_bib61","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2217\/fon-2022-0439","article-title":"Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors","volume":"18","author":"Porosnicu","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.omton.2026.201140_bib62","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/OV.S165479","article-title":"Three-dimensional tumor cell cultures employed in virotherapy research","volume":"7","author":"Kloker","year":"2018","journal-title":"Oncolytic Virother."},{"key":"10.1016\/j.omton.2026.201140_bib63","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1128\/JVI.02511-10","article-title":"Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism","volume":"85","author":"Muik","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201140_bib64","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000500159","article-title":"The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines","volume":"109","author":"Kloker","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.omton.2026.201140_bib65","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.omton.2026.201140_bib66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12250-020-00230-5","article-title":"On the Calculation of TCID(50) for Quantitation of Virus Infectivity","volume":"36","author":"Lei","year":"2021","journal-title":"Virol. Sin."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:25:23Z","timestamp":1778271923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2950329926000160"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201140","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The oncolytic vesicular stomatitis virus VSV-GP shows profound oncolytic activity in NUT-carcinoma cell lines","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201140"}}